References
- Golden T., Stout A. P Smooth muscle tumours of the gastrointestinal tract and retroperitoneal tissues. Surg Gynecol. Obstet, 1941, 73: 784–790.
- Stout A. P. Bizarre smooth muscle tumors of the stomach. Cancer, 1962, 15: 400–409.
- Welsh R. A., Meyer T. Ultrastructure of gastric leiomyomas. Arch Pathol, 1969, 87: 71–81.
- Ricci A., Ciccarelli O., Cartun R. W. et al. A clinicopathologic and immunohistochemical study of 16 patients with small intestinal leiomyosarcomas. Limited utility of phenotyping. Cancer, 1987, 60: 1790–1799.
- Mazur M. T., Clark H. B. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol, 1983, 7: 507–519.
- Michaela. I., Bacchi C. E., zarbo R. J. et al. CD34 expression in stromal tumors of the gastrointestinal tract. Appl Immuno-histochem, 1994, 2: 89–93.
- Sarlomo-Rikala M., Kovatich A. J., Barusevivius M. et al. CD117: a sensitive marker for a gastrointestinal stromal tumor that is more specific than CD34. Mod Pathol, 1998, 11: 728–734.
- Hirota S., Isozaki K., Moriyama Y. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279: 577–580.
- Heinrich M. C., Corless C. L., Duensing A. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299: 708–710.
- Hirota S., OhashiA., NishidaT. et al. Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology, 2003, 25: 660–667.
- Corless C. L., Fletcher J. A., Heinrich M. C. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol, 2004, 22: 38133825.
- Reichardt P., Hogendoorn P. C., Tamborini E. et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol, 2009, 34: 290–301.
- Stamatakos M., Douzinas E., Stefanaki C. et al. Gastrointestinal stromal tumor. World J Surg Oncol, 2009, 7: 61.
- Brabec P, Sufliarsky J., Linke घ. et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma, 2009, 56: 459–464.
- Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001, 438: 1–12.
- Sakurai S., HishimaT., Takazawa Y. et al. Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int, 2001, 51: 524–531.
- Clary B. M., De Matteo R. P, Lewis J. et al. Gastrointestinal stro-mal tumors and leiomyosarcoma of the abdomen and retroperi-toneum: a clinical comparison. Ann Surg Oncol, 2001, 8: 290299.
- Neto M. R., Machuca T. N., Pinho R. V. et al. Gastrointestinal stromal tumor: report of two unusual cases. Virchows Arch, 2004, 444: 594–596.
- Ortiz-Hidalgo e., Bojorge B. L., Albores-Saavedra J. Stromal tumor of the gall bladder with phenotype of interstitial cells of Cajal. A previously unrecognized neoplasm. Am J Surg Pathol, 2000, 24: 1420–1423.
- Daum O., Klecka J., Ferda J. et al. Gastrointestinal stromal tumor of the pancreas: case report with documentation of KIT gene mutation. Virchows Arch, 2005, 446: 470–472.
- Lasota J., Carlsson J. A., Miettinen M. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. A clinical report with documentation of KIT expression and mutation. Arch Pathol Lab Med, 2000, 124: 894–897.
- Ceballos K. M., Francis J. A., Mazura J. L. Gastrointestinal stromal tumor presenting as a recurrent vaginal mass. Arch Pathol Lab Med, 2004, 128: 1442–1444.
- Fletcher C. D., Berman J. J., Corless C. et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol, 2002, 33: 459–465.
- Miettinen M., Majidi N., Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumours (GISTs). A review. Eur J Cancer, 2002, 38: 539–551.
- Miettinen M., Makhlouf H., Sobin L. H. et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long term follow-up. Am J Surg, 2006, 30: 477–489.
- Miettinen M., Sobin L. H., Lasota J. et al. Gastrointestinal stro-mal tumors of the stomach: a clinicopathologic, immunohisto-chemical, and molecular genetic study of 1,765 cases with longterm follow-up. Am J Surg pathol, 2005, 29: 52–68.
- Beltran M. A., Pujado B., Méndez P. E. et al. Gastric gastrointestinal stromal tumor (GIST) incidentally found and resected during laparoscopic sleeve gastrectomy. Obes Surg, 2010, 20: 393–396.
- Sexton J. A., Pierce R. A., Halpin V. J. et al. Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc, 2008, 22: 2583–2587.
- Kostka R., Fanta J., Masri A. (Myogenic tumours of the digestive tract). Cas Lek Cesk, 1999, 138: 366–368.
- Miettinen M., Sarlomo-Rikala M., Sobin L. H. et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol, 2000, 24: 1339–1352.
- Miettinen M., Kopczynski J., Makhlouf H. et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol, 2003, 27: 625–641.
- Yymaguchi U., HasegawaT., Mazura T. et al. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch, 2004, 445: 142–150.
- Daum O., Vanecek T., Síma R. et al. (Gastrointestinal stromal tumors-current view). Klin Onkol, 2006, 19: 203–11.
- Kocáková I. (Diagnostics and targeted biological therapy of the gastrointestinal stromal tumors). Medical Tribune, 2008, 17: C4.
- Demetri G. D., von Mehren M., Blanke C. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347: 472–480.
- Van Oosterom AT., Judein I., Verweij J. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet, 2001, 358: 1421–1423.
- Heinrich M. C., Corless C. L., Demetri G. D. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 2003, 21: 43424349.
- Debiec-Rychter M., Sciot R., Le Cesne A. et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 2006, 42: 1093–1103.
- Antonescu C. R., Sommer G., Sarran L. et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res, 2003, 9: 33293337.
- Blanke C. D., Demetri G. D., von Mehren M. et al. Long term results from a randomized phase ii trial of standard-versus higherdose imatinib mesylate for patients with unresectable or metastat-ic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 2008, 26: 620–625.
- DeMatteo R. P, Ballman K. V., Antonescu C. R. et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour. a randomissed, double-blind, placebo controlled trial. Lancet, 2009, 373: 1097–1104.
- Heinrich M. C., Maki R. G., Corless C. L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 2008, 26: 5352–5359.
- Le Torneau C., Raymond E., Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag, 2007, 3: 341–348.
- Liegl-Atzwanger B., Fletcher J. A., Fletcher C. D. M. Gastrointestinal stromal tumors. Virchows Arch, 2010, 456: 111127.